title: Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study.
abstract: OBJECTIVE
  Non-alcoholic fatty liver disease (NAFLD) is an established risk factor for diabetes, cardiovascular disease, antiviral treatment resistance, and progression of chronic hepatitis C virus (HCV) infection to fibrosis. Apolipoprotein-B 100 (ApoB-100) is a dyslipidemia marker and steatosis predictor. We assess the correlation between ApoB-100 and hepatosteatosis.
  
  
  METHODS
  This cross-sectional study enrolled 1,218 HCV-seropositive participants from a 2012-2013 health checkup in Taiwan. NAFLD was detected using ultrasound. All anthropometric and laboratory studies that included ApoB-100 were evaluated whether or not ApoB-100 predicts NAFLD. Logistic regression was also used to examine the association between ApoB-100 and NAFLD.
  
  
  RESULTS
  Participants were 47.16 ± 16.08 years old (mean age). The overall prevalence of NAFLD was 35.8% (n = 436; 32.8% men, 38.1% women). Participants with ApoB-100 ≥ 8 had a significantly higher incidence of NAFLD (39.4 vs. 29.4%; 95% CI 0.044-0.156; p < 0.001). After confounding factors had been adjusted for, ApoB-100 was significantly associated with NAFLD (OR 5.45; 95% CI 1.64-18.06; p = 0.006) and high-grade hepatosteatosis (OR 7.73; 95% CI 1.74-34.35; p = 0.007).
  
  
  CONCLUSIONS
  ApoB-100 is strongly associated with NAFLD in people with non-genotype 3 HCV; greater ApoB-100 content is significantly correlated with higher-grade hepatosteatosis.
authors.affiliation: Division of Cardiology, Chang Gung Memorial Hospital, Yunlin, Taiwan.
authors.forename: Ming-Shyan
authors.initials: MS
authors.lastname: Lin
authors.forename: Su-Er
authors.initials: SE
authors.lastname: Guo
authors.forename: Huang-Shen
authors.initials: HS
authors.lastname: Lin
authors.forename: Jen-Te
authors.initials: JT
authors.lastname: Hsu
authors.forename: Yu-Sheng
authors.initials: YS
authors.lastname: Lin
authors.forename: Tsai-Hui
authors.initials: TH
authors.lastname: Lin
authors.forename: Tung-Jung
authors.initials: TJ
authors.lastname: Huang
authors.forename: Mei-Yen
authors.initials: MY
authors.lastname: Chen
authors.forename: Chang-Min
authors.initials: CM
authors.lastname: Chung
mesh_terms: D000328:Adult; D000368:Aged; D053299:Apolipoprotein B-100 / Q000097:blood*; D003430:Cross-Sectional Studies; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000821:virology; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood* / Q000000981:diagnostic imaging / Q000821:virology; D015995:Prevalence; D012307:Risk Factors; D013624:Taiwan; D014463:Ultrasonography
chemical_list: D053299:Apolipoprotein B-100